This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: February 2010.
Drs. Zaleski and Turiansky report no conflict of interest. The authors report no discussion of off-label use. Dr. Fisher reports no conflict of interest. The staff of CCME of Albert Einstein College of Medicine and Cutis® have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Dr. Zaleski was General Medical Officer, Expeditionary Health Services Atlantic Fleet, Norfolk, Virginia, and currently is a dermatology resident, Naval Medical Center, San Diego, California. Dr. Turiansky is Professor of Dermatology, Uniformed Services University of Health Sciences, Bethesda, Maryland, and Program Director, National Capital Consortium Dermatology Residency Program, Bethesda; Dermatology Service, Walter Reed Army Medical Center, Washington, DC; and Dermatology Department, National Naval Medical Center, Bethesda. The views expressed in this article are those of the authors and do not reflect the official policy of the US Department of the Army, US Department of the Navy, US Department of Defense, or US Government.
Lisa Zaleski, DO; George W. Turiansky, MD
Squamous cell carcinoma of the anal canal (SCCAC) is an increasing concern in the human immunodeficiency virus (HIV)–positive population in the highly active antiretroviral therapy (HAART) era. A discussion of the epidemiology, risk factors, clinical presentation, diagnosis, and treatment of SCCAC is presented.
